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BACKGROUND: The von Hippel–Lindau gene (VHL) alteration, a common event in sporadic clear-cell renal-cell carcinoma (CCRCC),
leads to highly vascularised tumours. Vascular endothelial growth factor (VEGF) is the major factor involved in angiogenesis, but the
prognostic significance of both VHL inactivation and VEGF expression remain controversial. The aims of this study were to analyse the
relationship between VHL genetic and epigenetic alterations, VHL expression and VEGF tumour or plasma expression, and to analyse
their respective prognostic value in patients with CCRCC.
METHODS: A total of 102 patients with CCRCC were prospectively analysed. Alterations in VHL were determined by sequencing,
Multiplex Ligation-dependent Probe Amplification (MLPA) and methylation-specific MLPA. Expression of pVHL and VEGF was
determined by immunohistochemistry. Plasma VEGF was measured by enzyme-linked immunosorbent assay (ELISA).
RESULTS: VHL mutation, deletion and promoter methylation were identified in 70, 76 and 14 cases, respectively. Overall, at least one
VHL-gene alteration occurred in 91 cases (89.2%). Both VEGF tumour and plasma expression appeared to be decreased in case of
VHL alteration. Median progression-free survival and CCRCC-specific survival were significantly reduced in patients with wild-type
VHL or altered VHL and high VEGF expression, which, therefore, represent two markers of tumour aggressiveness in CCRCC.
CONCLUSION: Stratifying CCRCCs according to VHL and VEGF status may help tailor therapeutic strategy.
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Renal-cell carcinoma (RCC) accounts for 3% of all solid tumours.
Seventy-five to 85% of RCCs are clear-cell carcinomas (clear-cell
renal-cell carcinoma (CCRCC)), which are highly vascularised
tumours. As much as 30% of patients do have metastases at the
time of diagnosis and an additional 30–40% will develop
metastases during follow-up, although a radical surgery has been
initially performed (Rabinovitch et al, 1994). Significant progresses
have recently been made in the medical treatment of metastatic
RCC by targeting a number of growth factors, including vascular
endothelial growth factor (VEGF) and platelet-derived growth
factor (PDGF) and their receptors (Motzer and Bukowski, 2006;
Patard et al, 2008a). Indeed, median progression-free survival
(PFS) time has been doubled either in first-line or in second-line
therapy by targeting tumour angiogenesis (Motzer et al, 2007).
The von Hippel–Lindau (VHL) tumour suppressor has been
isolated in 1993 (Latif et al, 1993). The protein encoded by the VHL
gene (pVHL) is the substrate recognition component of a ubiquitin
ligase complex that targets a transcription factor, hypoxia-
inducible factor (HIF), for proteolysis. A biallelic VHL inactivation
leads to HIF-1a accumulation and subsequent overexpression of
genes, which are critical for tumour angiogenesis, cell proliferation
and migration (Knebelmann et al, 1998; Cockman et al, 2000; Kim
and Kaelin, 2004).
Although some studies have shown a positive relationship
between genetic and epigenetic VHL gene alterations and VEGF
tumour overexpression (Igarashi et al, 2002; Na et al, 2003),
literature results are conflicting especially regarding the associa-
tion between VHL mutation, usual prognostic parameters and
survival (van Houwelingen et al, 2005; Schraml et al, 2002; Yao
et al, 2002). In a recent study we have demonstrated that the
absence of VHL mutation, associated with low Carbonic Anhydrase
IX (CAIX) tumour expression, was associated to a particular
aggressive CCRCC phenotype (Patard et al, 2008b). Both CAIX and
VEGF are VHL/HIF downstream targets, but unlike CAIX, which is
a surrogate indicator for VHL status, VEGF regulation is much
more complex. Conflicting hypotheses also exist regarding its
prognostic value in CCRCC (Jacobsen et al, 2002). Therefore, we
aimed this prospective study for evaluating the association
between VHL status (mutation, deletion, promoter methylation
and pVHL expression), tumour VEGF expression, plasma VEGF
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quently analysed the respective prognostic value of these different
biological tumour characteristics.
MATERIALS AND METHODS
Study population
A total of 102 patients operated for a sporadic CCRCC at the
Department of Urology at the Rennes University Hospital between
2003 and 2004 were analysed. In case of distant metastases,
patients were treated following surgery according to the standard
of care of the period, which was immunotherapy. Surveillance
following surgery included repeated clinical assessments, blood
biochemistry tests, chest and abdominal CT scans. No patient was
lost to follow-up. The study protocol was approved by the
institutional ethics committee and informed consent for partici-
pating in this study was obtained in each case. The clinicopatho-
logical data of the patients are summarised in Table 1.
Pathological analysis
Formalin-fixed paraffin sections were stained with hematoxylin
and eosin–safran for light microscopy. The slides were reviewed
by one pathologist (N Rioux-Leclercq). Only conventional CCRCCs
were considered for analysis. Macroscopic and histological
parameters, which were analysed included tumour size, tumour
necrosis and nuclear Fuhrman grade (Fuhrman et al, 1982;
Rioux-Leclercq et al, 2007b). Tumour stage was defined according
to the TNM classification (Guinan et al, 1997).
Tissue sample management
All consecutive conventional CCRCCs and paired renal cortex
samples from untreated patients undergoing partial or total
nephrectomy were analysed. Immediately after macroscopic
examination, small samples were collected from surgical speci-
mens, frozen in liquid nitrogen and stored at –801C. Genomic
DNA was extracted using QIAamp DNA minikit (Qiagen,
Courtaboeuf, France).
VEGF plasma measurement
Blood samples were collected before nephrectomy and processed
as described (Rioux-Leclercq et al, 2007a). The plasma was stored
at  801C until analysed. Quantikine human VEGF Immunoassay
(R&D Systems Europe, Lille, France) enzyme-linked immuno-
sorbent assay (ELISA) was performed to quantitate VEGF levels
(VEGF121 and VEGF165 free isoforms) in plasma. All samples were
assessed in duplicate. The value of plasma VEGF (pVEGF) was
expressed in pg/ml. The detection limit of the test was 9pg
 1ml
and the upper limits of normal value used for VEGF in plasma was
62.5pgml
 1 (Adams et al, 2000).
VEGF and pVHL tumour immunostaining
In each case, a representative slide of the tumour with the highest
nuclear Fuhrman grade and the corresponding paraffin block were
selected for immunohistochemistry. Tissue sections were depar-
affinised in xylene using standard procedures.
For VEGF immunostaining, antigen retrieval was performed by
immersing sections in a 0.01 M sodium citrate buffer (pH 6.0) and
heated in a 600W microwave four times for 2min. The slides were
then left to cool down for 30min and rinsed in a phosphate-
buffered saline solution. Slides were incubated at room tempera-
ture for 1h with the polyclonal anti-VEGF antibody (sc-152,
dilution 1/100; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
A biotin–streptavidin detection system (Dako, Glostrup,
Denmark) was then used with diaminobenzidine as the chromogen
(Sigma-Aldrich, Lyon, France). Negative controls were performed
by omitting the primary antibody and by incubating primary
antibody with immunising VEGF peptide prior to slide treatment.
VEGF immunoreactivity was expressed as the percentage of the
VEGF-positive cells by scoring at least 1000 tumour cells at  400
magnification. The immunohistochemical signals in the CCRCCs
were evaluated as membranous and/or cytoplasmic. For prognostic
analysis, a 30% cut-off was used according to previous reports
(Jacobsen et al, 2004).
pVHL immunohistohemical staining of tissue sections was
performed with a monoclonal anti-pVHL antibody (Ig33;
Neomarkers, Fremont, CA, USA; Schraml et al, 2003; Valle et al,
2005), in an automated stainer using the ultraview DAB detection
kit (Benchmark; Ventana, Tucson, AZ, USA) following antigen
retrieval. Semi-quantitative assessment of the antibody staining
was performed by a single uropathologist blinded to the
clinicopathological variables (N Rioux-Leclercq). A negative
control consisted of omitting the primary antibody. As control
for loss of pVHL expression, CCRCC tissue from confirmed VHL
genetic disease was used. The extent of staining was recorded as
a percentage of the tumour tissue sample with positive pVHL
expression. Tumours expressing pVHL were scored pVHLþ,
independently of the percentage of stained cells.
VHL mutational analysis
We amplified two overlapping fragments for exon 1 (1A and 1B)
and one fragment for each of exons 2 and 3, covering part of the
VHL 50UTR, the entire coding sequence and exon–intron
junctions (VHL GenBank accession no. AF010238). Primer pairs
and PCR-sequencing conditions are described elsewhere (Patard
et al, 2008b). Denaturing high-performance liquid chromatography
(DHPLC) screening was carried out on a WAVE Nucleic Acid
Table 1 Summary of the clinical and histopathological characteristics of
the 102 patients with sporadic CCRCC
Variables Value/number
Age (years) 64.5 (21–83)
Sex (male/female) 44 (43.1%)/58 (56.9%)
Tumour size (cm) 7 (1.5–22)
Fuhrman grade
1 2 (1.9%)
2 35 (34.3%)
3 37 (36.3%)
4 28 (27.5%)
Tumour stage
1 38 (37.3%)
2 20 (19.6%)
3 40 (39.2%)
4 4 (3.9%)
Lymph node status
0 90 (88.3%)
1 8 (7.8%)
2 4 (3.9%)
Metastasis status
0 73 (71.6%)
1 29 (28.4%)
Abbreviation: CCRCC¼clear-cell renal-cell carcinoma. Pathological diagnosis is
according to the Fuhrman grading system and UICC tumour-node-metastasis staging
system. Values are presented as median (minimum maximum) for continuous
variables and number of patients (percent) for categorical variables.
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sFragment Analysis system (Transgenomic, Glasgow, UK) with a
DNAsep column. Aberrant peaks were further analysed by direct
sequencing using standard procedures. All mutations were
confirmed in a second PCR and sequencing reaction.
VHL deletion analysis
Multiplex Ligation-dependent Probe Amplification (MLPA)
analysis was used to detect deletions or duplications in the
VHL gene (Schouten et al, 2002). The SALSA MLPA P016B VHL
probe kit (MRC-Holland, Amsterdam, the Netherlands) was used.
The kit contains eight probes to the VHL gene (four in exon 1, two
in exon 2 and two in exon 3), additional probes to other genes on
3p and control probes to regions telomeric and centromeric from
VHL. Detailed information on probe sequences, gene loci and
chromosome locations can be found at www.mlpa.com.
Genomic DNA (50–200ng) was denatured and the probes were
allowed to hybridise (16h at 601C). PCR was performed on the
samples in a volume of 50ml containing 10ml of the ligation
reaction mixture using the PTC 200 thermal cycler (MJ Research,
Waltham, MA, USA). Aliquots of 1.5ml of the PCR reaction were
combined with 0.3ml ROX-labelled internal size standard (Applied
Biosystems, Foster City, CA, USA) and 9ml deionised formamide.
Fragments were separated by electrophoresis on an Applied
3130XL capillary sequencer and quantified using the GeneMarker
version 1.6 software (SoftGenetics). For copy-number detection,
normal control DNA samples were included in each set of MLPA
experiments. Interpretation was based on the comparison of peak
heights between the control DNA and the tumour sample. Cut-off
levels for loss of relative copy number were set at 0.75.
VHL promoter methylation analysis
Methylation-Specific-MLPA (MS-MLPA) was used to detect CpG
island methylation (Jeuken et al, 2007). The probe design is similar
to an ordinary MLPA probe, except that, for the methylation-
specific probes, the sequences detected contain a methylation-
sensitive restriction site (HhaI). The SALSA MS-MLPA kit ME001B
Tumour suppressor-1 allows to detect aberrant methylation of
CpG islands located in the promoter region of the VHL gene. DNA
(50–200ng) was denatured and the probes were allowed to
hybridise (16h at 601C). The VHL probes used in this study for
methylation quantification analysis contained one HhaI restriction
site in the target recognition sequence. Following hybridisation,
the samples were divided into two and one half of the samples was
ligated, whereas for the other part of the sample ligation was
combined with HhaI digestion enzyme. This digestion resulted in
ligation of only the methylated sequences. PCR was performed on
both parts of the samples and analysed by electrophoresis as
described above. Reference unmethylated DNAs, isolated
from blood from healthy volunteers, were included in each set of
MLPA experiments. The unmethylated DNA will not generate a
signal, and a normal probe signal will be detected if the site is
methylated.
Statistical methods
w
2-test and Student’s t-test were used for comparing qualitative
and quantitative variables, respectively. Kaplan–Meier method
and log-rank test were used for comparing survival in different
groups. Endpoints for outcome assessment were PFS, which
was defined as the time of surgery to the occurrence of local
recurrence or distant metastases, and RCC-specific survival
(RCC-SS), which was defined as death from RCC .All analyses
were conducted with the SPSS 10.1 software, and P-value
significance was fixed at 0.05.
RESULTS
Patients and tumour characteristics
Sixty-eight (66.7%) and 51 patients (50%) had good performance
status and no symptoms at diagnosis, respectively. Tumours were
organ-confined (pT1-2) and low-grade (G1-2) in 58 (56.9%) and 37
cases (36.3%), respectively (Table 1). In 12 cases, nodal invasion
was present at diagnosis (11.7%) and in 29 cases (28.4%) patients
had synchronous distant metastases. During a median follow-up
time of 31 months (1–62), 40 patients (39.2%) experienced disease
progression and 27 subsequently died from cancer (26.5%).
Genetic and epigenetic VHL gene alteration – relationship
with clinicopathological variables and outcome
A VHL gene mutation was found in 70 cases (68.6%). Mutations
occurred in exon 1–3 in 30 (42.8%), 26 (37.2%) and 14 cases (20%),
respectively. Stop, frameshift, missense, splice site and other mutation
types were found in 10 (14.3%), 31 (45.7%), 19 (27.1%), six (8.6%)
and four cases (4.3%), respectively (Supplementary Table S1).
Although there was a trend for better PFS and RCC-SS in patients
with VHL-mutated tumours, it did not achieve statistical significance
(log-rank test, P¼0.1 and 0.2, respectively). Mutation type and site of
mutation did not impact either on PFS or on RCC-SS.
VHL deletion and promoter methylation occurred in 76 (74.5%)
and 14 cases (13.7%), respectively (Figure 1A). Overall, VHL
0.2
0.4
0.6
0.8
1.0
10
Follow-up (months)
R
C
C
-
s
p
e
c
i
f
i
c
 
s
u
r
v
i
v
a
l
no VHL alteration
VHL mutated, deleted
or methylated
Log-rank test, P = 0.02
VHL mutation
VHL deletion
VHL methylation
14
(13.7%) 55
(53.9%)
8
(7.8%)
0
(0%)
1
(1.0%)
12
(11.8%)
1
(1.0%)
No VHL alteration
11
(10.8%)
20 30 40 50
Figure 1 Alteration of the VHL gene in 102 CCRCC tumours.
(A) Distribution of the different VHL alterations identified. (B) Cause-
specific survival curve for patients with CCRCC based on VHL alterations
(solid line, mutation, deletion or methylation of the VHL gene, n¼91,
89.2%; broken line, no VHL alteration, n¼11, 10.8%).
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smutation, deletion or hypermethylation occurred in 91 cases
(89.2%). When considering patients with no VHL mutation,
deletion or hyper-methylation (n¼11, 10.8%), it appeared that
their outcome was significantly worse both for PFS and RCC-SS
than patients having at least one VHL alteration (log-rank test,
P¼0.02; Figure 1B). This group was significantly associated with
higher N stages (P¼0.007) and Fuhrman grades (P¼0.03).
At least two alterations of the VHL gene, potentially leading to
biallelic alteration, were found in 68 tumours (66.7%), whereas no
or a single alteration of the VHL gene was found in 34 patients
(33.3%). Comparison of these two groups yielded borderline
prognostic significance for PFS (log-rank test, P¼0.05) but not for
RCC-SS (log-rank test, P¼0.2). There was no relation with tumour
size (P¼0.6), T stage (P¼0.2), N stage (P¼0.4) or M stage
(P¼0.7).
pVHL pattern of expression and relationship with
clinicopathological variables
In normal kidney, a strong cytoplasmic staining was observed in
tubular cells as well as a weak staining in mesangial cells. In
tumours showing pVHL expression, the staining was strong,
diffuse and cytoplasmic. pVHL tumour expression was not
detected in 71 cases (69.6%). The absence of pVHL expression
was associated with lower N stages (P¼0.02), M stages (P¼0.01),
Fuhrman grades (P¼0.001; Figure 2A) along with lower
rates of tumour necrosis (P¼0.005). Finally, absence of pVHL
expression was associated with a more favourable outcome
measured both by PFS (P¼0.02) and RCC-SS (log-rank test,
P¼0.03; Figure 2B).
When selecting tumours with undetectable pVHL and at least
one VHL alteration (n¼67, 68.4%) and comparing this former
group to tumours expressing pVHL (n¼31, 31.6%), the first group
exhibited better outcome both in terms of PFS (log-rank test,
P¼0.02) and in terms of RCC-SS (log-rank test P¼0.03;
Figure 3A). A small group of tumours (n¼7, 6.9%) expressed
pVHL and did not present any VHL alteration. This group had a
median PFS of 7 months compared with 58 months for the rest of
the population (log-rank test, P¼0.004). The median RCC-SS time
was 18 months for this particular group with no VHL abnormality,
whereas it was not reached for the rest of the population (log-rank
test P¼0.001; Figure 3B).
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Figure 2 pVHL expression in CCRCC. (A) Percentage of tumour tissue
with positive pVHL expression according to Fuhrman grade. Horizontal
lines represent mean values. (B) Cause-specific survival curve for patients
based on pVHL expression (solid line, tumours not expressing pVHL,
n¼71, 69.6%; broken line, tumours expressing pVHL, n¼31, 30.4%).
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Figure 3 Cause-specific survival curves for patients with CCRCC based
on VHL alterations and pVHL expression. (A) Survival curves for patients
with tumours not expressing pVHL and containing at least one VHL
alteration (solid line, n¼67, 68.4%), and for patients with tumours
expressing pVHL (broken line, n¼31, 31.6%). (B) Survival curves for
patients with tumours not expressing pVHL or containing at least 1 VHL
alteration (solid line, n¼95, 93.1%), and for patients with tumours
expressing pVHL and presenting no VHL alteration (broken line, n¼7,
6.9%).
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clinicopathological variables and outcome
Positive staining for VEGF was defined as a membranous and/or
cytoplasmic staining pattern of tumour cells. Weak staining was
observed in podocytes and endothelial cells in non-tumoral kidney
tissue. Median VEGF tumour expression was 49% (0–100). In 60
cases (58.8%) VEGF tumour expression was X30%. The expres-
sion of VEGF in tumour was associated with T stage (P¼0.03),
M stage (P¼0.03), Fuhrman grade (P¼0.001; Figure 4A) but not
with N stage (P¼0.2) or ECOG performance status (P¼0.4) (data
not shown).
Median VEGF plasma value was 92.5pgml
 1 (13–1430), which
is superior to what is reported for healthy donors (Adams et al,
2000). Plasma VEGF level was associated with T stage (P¼0.001),
Fuhrman grade (P¼0.005; Figure 4B), ECOG performance Status
(P¼0.02), but not with N stage (P¼0.07) or M stage (P¼0.5; data
not shown). Tumour and plasma VEGF were both predictors for
PFS (log-rank test, P¼0.01 and 0.002, respectively) and RCC-SS
(log-rank test, P¼0.05 and 0.001, respectively; Figure 4C). In
summary, increased plasma or tumour VEGF expression was
associated with more aggressive tumour pattern and poorer
outcome.
Relationship between pVHL, VHL and VEGF
A strong relationship was observed between VEGF tumour
expression, VEGF plasma level and pVHL detection (Table 2).
However, unexpectedly, the absence of pVHL detection was
associated with both lower VEGF tumour and plasma expression
(P¼0.0001 and 0.002, respectively). Similarly, tumours presenting
biallelic inactivation of the VHL gene were associated with
decreased VEGF tumour expression (P¼0.0001) and plasma
VEGF levels (P¼0.005; Table 2). Consistently, when selecting
tumours with no detectable pVHL and at least one VHL alteration,
it appeared that this latter group exhibited decreased VEGF
tumour expression (P¼0.0001) and VEGF plasma levels
(P¼0.002) compared with tumours expressing pVHL. Finally,
the group not harbouring any VHL abnormality (n¼11, 10.8%)
was also characterised by increased mean VEGF plasma
(309.8±281.9 vs 183.4±139.9pgml
 1, P¼0.03) and mean VEGF
tumour expression (77.4±32.4 vs 45.8±37.4, P¼0.009) compared
with tumours with either mutation, deletion or methylation of the
VHL gene (n¼91, 89.2%).
When focusing on the population with at least one VHL
alteration, it appeared that both VEGF tumour expression (cut-off
30%) and VEGF plasma level (cut-off, median value of
92.5pgml
 1) were able to stratify two population subsets with
distinct outcomes. Based on these finding, our total CCRCC
population was, therefore, stratified into three distinct
groups: Group 1, at least one VHL alteration and low VEGF
expression; Group 2, at least one VHL alteration and high
VEGF expression and Group 3, no VHL alteration regardless of
VEGF expression. When stratifying with plasma VEGF level, the
median PFS times for the three groups were 58, 27 and 17 months,
respectively (log-rank test, P¼0.005), whereas median RCC-SS
time was not reached for the first two groups and was 36 months
for the third group (log-rank test, P¼0.003; Figure 5A). When
stratifying the entire clear-cell population with VEGF tumour
expression, the median PFS times for the three groups were not
reached for the first group, was 58 months for the second group
and 17 months for the third group (log-rank test, P¼0.01). In the
latest setting, median RCC-SS time was not reached for the first
two groups and was 36 months for the third group (log-rank test,
P¼0.02; Figure 5B).
Multivariate analysis has been performed. Unfortunately, it did
not reach significance, probably because of the limited number of
tumours with no VHL alteration.
DISCUSSION
The importance of tumour angiogenesis in CCRCC development
and spreading has been recently strongly validated by the proven
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Figure 4 VEGF expression in CCRCC. (A) Percentage of tumour tissue
with positive VEGF expression according to Fuhrman grade. Horizontal
lines represent mean values. (B) Concentration of VEGF in the plasma of
CCRCC patients according to Fuhrman grade. Horizontal lines represent
mean values. (C) Cause-specific survival curve for patients based on VEGF
expression in plasma (solid line, patients with plasma VEGFo92.5pgml
 1,
n¼56, 50%; broken line, patients with plasma VEGF X92.5pgml
 1,
n¼56, 50%).
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pathway (Motzer et al, 2007; Figlin et al, 2008). Up till now, no
prognostic factor has been validated in this setting and there is
a growing need for defining biological tools for treatment
monitoring (Golshayan et al, 2008). In this prospective series, we
demonstrate that (1) VHL alterations appear to be associated with
a favourable outcome, (2) VEGF instead of being overexpressed in
VHL-inactivated tumours seems to be relatively low and (3) a small
cohort of CCRCC with no VHL alteration exhibit a very
unfavourable outcome.
Vascular endothelial growth factor upregulation mechanisms in
CCRCC remain hypothetical. It has been demonstrated that VEGF
is overexpressed both in tumour tissue and in blood samples in
CCRCC (Jacobsen et al, 2002; Rioux-Leclercq et al, 2007a). It is
generally believed that this overexpression is due to VHL
inactivation that occurs with a high frequency in sporadic CCRCC
(70–80%; Gnarra et al, 1994; Yao et al, 2002). Additionally, it is
postulated that VHL inactivation leads to HIF constitutive
expression and, therefore, induction of target genes including
VEGF. However, VHL-independent mechanisms could explain
VEGF upregulation and additional role have been described for
VHL in CCRCC tumorigenesis (Kim and Kaelin, 2004). Therefore,
there was a rationale for analysing in a cohort of sporadic CCRCC
the relationship between VHL alterations and VEGF plasma and
tumour expression.
In this series, we could confirm that plasma or tumour
VEGF were elevated in the majority of patients and that both high
plasma and tissue VEGF were associated with increased risk of
dying from CCRCC. Unexpectedly, mean VEGF tumour expression
and mean VEGF plasma levels were significantly increased in
tumours with no VHL alteration as compared with tumours
harbouring at least one VHL alteration. This trend was repro-
ducible when examining both pVHL and VHL gene. Additionally,
out of the 68 tumours with two or three VHL alterations,
which potentially alter both alleles of the gene, 33 (48.5%)
exhibited low VEGF tumour expression, and out of the 34
remaining tumours, 25 (73.5%) had high VEGF tissue expression.
It clearly suggests that VHL-independent mechanisms are involved
in VEGF upregulation in advanced CCRCC. Conversely, un-
expected low VEGF levels were found in tumours with VHL
alterations, indicating that VHL alteration does not necessarily
trigger tumour progression.
Using a sensitive approach for mutation detection, we found a
68.6% VHL mutational rate along with 74.5 and 13.7% deletion and
promoter methylation rates, respectively, which is consistent with
what is generally reported in the literature (Banks et al, 2006;
Nickerson et al, 2008). We also demonstrate that VHL abnorm-
alities were associated with a favourable outcome. Our results are
in accordance with the report of Yao et al (2002) who first
presented a correlation between VHL mutation and better
prognosis. Similarly, Parker et al (2005) demonstrated that absence
of pVHL detected by immunohistochemistry was associated with
improved cancer-specific survival. The present study is also in
accordance with our previous analysis focusing on VHL and CAIX
(Patard et al, 2008b) even though we failed to demonstrate here a
clear association between VHL gene status and early TNM stages
or grades.
Table 2 Relationship between VHL gene inactivation and VEGF tumour or plasma expression
2o r3VHL alteration
(n¼68)
0o r1VHL alteration
(n¼34) P-value
pVHL 
(n¼71)
pVHL+
(n¼31) P-value
Mean VEGF tumour expression (%±s.d) 40.3±35.5 68.9±36.5 0.0001 38.7±35.9 73.4±31.6 0.0001
VEGF tumour expression X30% 35 (51.5%) 25 (73.5%) 0.007 33 (46.5%) 27 (87.1%) 0.0001
Mean plasma VEGF level (pg/ml±s.d.) 116.4±90.4 323.2±238.4 0.005 112.9±87.0 326.8±250.2 0.002
VEGF plasma level X92.5 pg/ml 31 (45.6%) 19 (55.9%) 0.2 33 (46.5%) 17 (54.8%) 0.5
Presence of tumour necrosis 34 (50.0%) 17 (50.0%) 0.6 29 (40.8%) 22 (71.0%) 0.005
Abbreviations: pVHL¼von Hippel-Lindau protein; s.d.¼standard deviation; VEGF¼vascular endothelial growth factor; VHL¼the von Hippel–Lindau gene. Values are
presented as mean±s.d. for continuous variables and number of patients (percent) for
categorical variables
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Figure 5 Cause-specific survival curves for patients with CCRCC based
on VHL alterations and VEGF expression. (A) Survival curves for patients
based on VHL alterations and plasma VEGF (solid line, patients with at least
one VHL alteration and plasma VEGFo92.5pgml
 1, n¼48, 47.1%; dotted
line, patients with at least one VHL alteration and plasma VEGF
X92.5pgml
 1, n¼43, 42.1% and broken line, patients with a wild-type
VHL, n¼11, 10.8%). (B) Survival curves for patients based on VHL
alterations and tumour VEGF expression (solid line, patients with at least
one VHL alteration and less than 30% of cells expressing VEGF, n¼40,
39.2%; dotted line, patients with at least one VHL alteration and more than
30% of cells expressing VEGF, n¼51, 50.0% and broken line, patients with
a wild-type VHL, n¼11, 10.8%).
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status to clinicopathological parameters (Kondo et al, 2002) or
prognosis (Brauch et al, 2000; Kim et al, 2005; Smits et al, 2008),
and others linked VHL alteration with more advanced tumour
stages (Schraml et al, 2002). These discrepancies may be partially
explained by recruitment bias with an insufficient number of small
incidental tumours, or the fact that TNM grouping was used and
not separated in T, N and M stage. Methodological bias could
also be involved. For example, in most of the studies VHL
mutation analyses were performed on formalin-fixed, paraffin-
embedded material (Schraml et al, 2002; Smits et al, 2008). It has
already been shown for other genes that formalin fixation of
archival specimens can induce sequence alterations (Williams
et al, 1999; Marchetti et al, 2006). Finally, the way VHL is analysed
is also of importance. In most series, tumours with biallelic
inactivation of the VHL gene are compared with tumours
presenting at least one functional allele. When using this approach,
we did not find clear correlation with outcome. However, when
separating tumours with no VHL alteration and tumours with at
least one VHL hit, we were able to identify two groups non
comparable in frequency but with very distinctive clinicopatho-
logical features and outcome.
The discrepancy between VHL studies in CCRCC could also be
explained by the stage of cancer progression at which VHL
status was evaluated. From this point of view, our classification of
CCRCC into three different groups with different aggressiveness
behaviours according to VHL and VEGF is of interest. The two
VHL-altered groups with distinct prognostic profiles according to
VEGF expression could be reflecting a progression process. VHL
alteration, as it is now well admitted, occurs at an early stage
of a disease, thus leading to a relative decrease of VEGF expression
(Group 1 of our VHL/VEGF classification). These tumours are
generally good prognostic tumours that are likely to be cured by
surgery or that could be potentially good candidates for
immunotherapy in case of metastases. Carbonic Anhydrase
IX is generally overexpressed in such tumours and CAIX has been
proven to be a good selection criteria for response to interleukin-2-
based immunotherapy (Atkins et al, 2005; Patard et al, 2008b).
Tumours with VHL alterations and high VEGF levels
(Group 2) probably reflect additional molecular events following
initial VHL alteration. These tumours with VEGF-driven aggres-
siveness would be good candidates for receiving tyrosine kinase
inhibitors (TKIs) that target VEGF-R and PDGF-R. It is probably
in this particular group that VEGF should be evaluated in the
future as a predictive factor for response to TKIs. Two different
studies suggested that tumours with loss of function of VHL were
more likely to be sensitive to anti-VEGF drugs, thus suggesting
that both VHL and VEGF status are potentially important for
predicting response to TKIs (Rini et al, 2006; Choueiri et al,
2008b).
The third group with no VHL alteration could be seen either as a
distinct molecular entity with no involvement of the VHL pathway.
From this point of view it is interesting to note that the survival of
patients with poor prognostic metastatic RCC according to the
Memorial Sloan-Kettering Hospital Cancer Center (MSKCC)
classification is increased by using mTOR inhibitors that do not
target specifically the VHL/VEGF pathway (Hudes et al, 2007;
Motzer et al, 2008). It is also interesting to note that non-clear-cell
RCCs, which are never VHL-mutated, seem to be less sensitive to
VEGF targeting drugs than their clear-cell counterpart, and that by
contrast non-clear-cell RCCs seem to be sensitive to mTOR
inhibitors (Choueiri et al, 2008a). Consistent with that vascular
phenotype selection hypothesis, metastatic CCRCC after an initial
phase of response to TKIs inevitably escape and progress.
In conclusion, classifying CCRCC according to VHL/VEGF
status could potentially help physicians to choose the appropriate
therapeutic strategy according to the molecular stage of the
disease: surgery/immunotherapy, surgery/TKIs and mTOR inhibi-
tors. We investigated a relatively small series of 102 patients with
CCRCC. Consequently, subgroups are limited in size. A larger
number of tumours with no VHL alteration would be needed to
validate further our hypotheses through prospective clinical trials,
and non-VHL molecular pathways that are involved in CCRCC
should be better characterised.
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